SCHEMBL1543430

SCHEMBL1543430

CCN1CCN(C(=O)C2(C#N)CCCC(N(Cc3ccccc3)Cc3ccccc3)C2)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.44
KDM4E B2RXH2 2/20 0.41
CCR5 P51681 1/20 0.40
USP30 Q70CQ3 1/20 0.40
CHRM1 P11229 2/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
OPRM1 P35372 2/20 0.38
RAB9A P51151 1/20 0.37
KDM1A O60341 1/20 0.36
PREP P48147 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543248 0.91 CCR5 (0.41) HSD11B1CCR5USP30CHRM1ALDH1A1
SCHEMBL1543657 0.87 SMN1; SMN2 (0.41) KDM4ECCR5USP30ALDH1A1MEN1
SCHEMBL1543234 0.81 MEN1 (0.40) KDM4ECCR5USP30ALDH1A1MEN1
SCHEMBL1543068 0.80 POLB (0.42) KDM4ECCR5ALDH1A1MEN1KMT2A
SCHEMBL1543586 0.80 MAPK1 (0.38) KDM4ECCR5USP30ALDH1A1MEN1
SCHEMBL1543519 0.76 HSD11B1 (0.44) HSD11B1KDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL21733050 0.71 HSD11B1 (0.49) HSD11B1KDM4E
SCHEMBL19583039 0.70 CCR5 (0.44) KDM4ECCR5ALDH1A1MEN1KMT2A
SCHEMBL13734746 0.68 TRPA1 (0.51) KDM4ECCR5ALDH1A1MEN1KMT2A
SCHEMBL14657441 0.68 TRPA1 (0.51) KDM4ECCR5ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307377-A1 NICOTINAMIDE DERIVATIVES Pfizer Limited (GB) 2011-04-13 EP disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173888-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 HSD11B1 1099/4885KDM4E 3753/4885CCR5 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.